On April 14, 2026, CMS published the 2026 Interoperability Standards and Prior Authorization for Drugs Proposed Rule (CMS-0062-P) in the Federal Register. The public comment window is open until June 15. For Florida’s 75,000-plus licensed MDs and DOs who have watched prior authorization swallow staff hours for years, this is the single most consequential administrative reform under active rulemaking, and the commenting period is short.
The rule matters. It extends the electronic prior authorization framework of the 2024 final rule (CMS-0057-F) from medical items and services to drugs, and it sets decision-time ceilings: 24 hours for urgent requests, 72 hours for standard. It adopts FHIR-based standards to replace the aging X12N 278 transaction format. And it requires impacted payers (Medicare Advantage plans, Medicaid managed care organizations, CHIP managed care entities, and qualified health plans on the federally-facilitated exchanges) to publish denial and appeal data.
Here is what the rule actually does, where the gaps are, and why every Florida physician should file a comment before June 15.
What CMS-0062-P Requires
The proposed rule has three operative pieces.
First, decision timeframes. Impacted payers must render prior authorization decisions for drugs no later than 24 hours after receiving an urgent request and 72 hours after a standard request. Today, Medicare Advantage plans have up to 72 hours for urgent and 14 days for standard, and commercial timelines are often worse. For a Florida primary care practice managing Medicare Advantage-dominant panels (roughly 55% of Florida Medicare beneficiaries are in MA plans as of 2026), the compression alone would meaningfully change what happens between the exam room and the pharmacy counter.
Second, electronic workflow. Payers must support an API-based prior authorization workflow using HL7 FHIR standards. This is the piece that could actually reduce the labor cost of prior auth. A properly implemented FHIR prior auth API lets the EHR submit the request, attach supporting clinical data, and receive a decision without phone calls or fax-backs. CMS is proposing compliance dates beginning in 2027, which is slow, but the direction is correct.
Third, transparency. Payers must publish aggregated data on their prior authorization approval, denial, and appeal reversal rates, broken down by request type. This is the structural change that makes the other two pieces enforceable. Physicians and employers can finally see which plans deny at 30% versus 8%, and whether denials are being overturned on appeal at high enough rates to suggest the original decisions were wrong.
Where the Rule Falls Short
The rule covers Medicare Advantage, Medicaid MCOs, CHIP MCOs, and FFM QHPs. It does not cover commercial group plans regulated under ERISA, which is where most working Florida physicians’ patients actually get coverage. Florida Blue’s PPO products, UnitedHealthcare’s large-group offerings, Aetna commercial, Cigna commercial: none of these plans are directly reached by the rule.
The effect is a bifurcated prior authorization regime: a patient in a Florida Medicare Advantage plan gets a 24-hour decision, their next-door neighbor in a Florida Blue commercial PPO waits two weeks. For practices that treat both populations, it doubles the workflow complexity rather than simplifying it.
The rule also contains no penalties for missed deadlines. A payer that blows past the 72-hour window faces no automatic consequence beyond whatever state insurance regulators choose to pursue. Florida’s Office of Insurance Regulation has the authority to act, but enforcement historically has been inconsistent, particularly on Medicare Advantage plans that argue federal preemption.
And the “urgent” definition is payer-controlled. A payer that classifies a request as standard rather than urgent gets the 72-hour window instead of 24, and there is no meaningful review mechanism for that classification decision in the rule as drafted.
What Florida Physicians Should Say in Comments
CMS reads comments. The 2024 final rule (CMS-0057-F) was materially strengthened on the basis of physician comments that pushed back on weaker draft timeframes. The proposed drug rule will go the same way if physicians show up.
Effective comments are specific, clinical, and include cases. Three angles worth pressing.
Expand the definition of urgent
Push CMS to codify specific clinical scenarios that must be treated as urgent: oncology, organ rejection prevention, acute infection, post-op pain, mental health crisis prescribing. Payers should not have discretion to classify an oncologist’s request for a next-line chemotherapy agent as “standard” and take 72 hours. If you have seen this happen in your practice, describe it.
Require plan-level enforcement mechanisms
Comment that the 24 and 72-hour windows need consequences. Suggest that missed deadlines default to approval, which is the approach several state-level prior auth reform laws have taken. Currently, missing the deadline just means the physician has to escalate, which costs more staff time, not less.
Close the ERISA gap or create equivalent state-level authority
CMS cannot directly regulate self-funded ERISA plans, but it can and should use its bully pulpit to encourage Congress to extend parity. At the state level, support expansions of the Florida prompt-pay statute (627.6131) to cover prior authorization timeframes for all regulated commercial plans. A federal rule that reaches Medicare Advantage but leaves commercial untouched creates a two-tier system that hurts exactly the patients who can least afford delay.
What to Do in Your Practice Right Now
-
File a comment. Go to regulations.gov, search for CMS-0062-P, and file before June 15. Individual physician comments carry weight that association comments do not. Speak in your own voice, cite specific patient cases (anonymized), and name the clinical harm caused by the current system.
-
Measure your own prior auth burden. If you can pull it from your practice management system: how many prior auths did your practice submit last quarter? What was the denial rate? How many were overturned on appeal? These numbers become your comment, and they become your negotiating position if you sit down with payers later this year (see our contract-negotiation playbook).
-
Identify your FHIR readiness. The rule’s 2027 compliance date sounds distant, but EHR vendors will start selling upgrade packages by Q3 2026. Understand whether your current EHR handles FHIR prior auth natively or whether your vendor will try to charge for a module. Epic, Athena, and eClinicalWorks are well-positioned; smaller vendors are behind.
-
Coordinate with the FMA and your specialty society. The Florida Medical Association is preparing coordinated comments. If your society wants case data, send it. Prior auth reform has been a rare area of bipartisan physician agreement, and the comment volume matters.
-
Audit your appeals process. The transparency provision means payer-by-payer appeal reversal rates will eventually be public. If your practice is under-appealing denied prior auths (national average is about 1 in 10), you are leaving medicine and money on the table. Hire the staff time or the outside service.
The comment window is eight weeks. Physicians who file move the rule. Physicians who wait for their association to handle it cede the pen.
Frequently Asked Questions
What is CMS-0062-P and when is the comment deadline?
CMS-0062-P is the 2026 Interoperability Standards and Prior Authorization for Drugs Proposed Rule, published in the Federal Register on April 14, 2026. The public comment period closes June 15, 2026. Comments can be filed at regulations.gov.
Does the CMS drug prior authorization rule apply to commercial plans in Florida?
No. The rule covers Medicare Advantage, Medicaid managed care organizations, CHIP managed care entities, and qualified health plans on the federally-facilitated exchanges. Self-funded ERISA commercial plans and state-regulated commercial plans are not directly reached. That gap is one of the most-criticized features of the draft.
How short are the new prior authorization decision windows for drugs?
The proposed rule sets a 24-hour decision ceiling for urgent requests and a 72-hour ceiling for standard requests. Current Medicare Advantage timelines allow 72 hours for urgent and up to 14 days for standard drug prior authorizations, so this is a substantial compression.
When would Florida physicians see the changes in their workflow?
CMS is proposing compliance dates beginning in 2027, meaning payers would need to meet the new timeframes and support FHIR-based electronic prior auth starting that year. Some larger payers may voluntarily adopt earlier; expect implementation details to continue shifting as the final rule is written through late 2026.
Should individual Florida physicians file CMS comments or leave it to the FMA?
Both. Individual physician comments with specific clinical cases carry weight that association comments do not, and CMS explicitly weighs comment diversity in its regulatory impact analysis. The FMA and specialty societies will file coordinated comments, but they are complementary to, not a substitute for, direct physician input.